In Memoriam: Our friend and Xconomist Rathindra Bose passed away on July 10, 2015. We at Xconomy are deeply saddened by his loss.

Rathindra N. Bose received his Ph.D. degree in chemistry from Georgetown University in 1982. Currently, he is serving as the Vice Chancellor/Vice President for Research and Technology Transfer at the University of Houston System and University of Houston. He holds a tenure professorial appointment with the departments of Chemistry and Biology and Biochemistry. He has served in a similar capacity at Ohio University, Northern Illinois University, and Kent State University. His notable administrative accomplishments include the creation of state-of-the-art research facilities, new multidisciplinary research institutes, multidisciplinary doctoral programs, and numerous spin-off companies; fostering partnerships with private and public sectors; and the enhancement of royalty income and extramural funding.

During his tenure, Dr. Bose has served with distinction as a faculty member. He has received a distinguished scholar award and four outstanding/distinguished teaching awards. He was also nominated by Kent State University for the 1997 CASE U.S. Professor of the year award. He has published extensively in his own field as well as interdisciplinary/multidisciplinary areas that extend to cancer biology and materials science. In addition, nine patent applications on cancer drugs and fuel cell electrocatalysts are either issued or currently pending with the United States Patent and Trademark office. He has delivered numerous talks as an invited symposium and plenary speaker both at national and international meetings. He has successfully supervised dissertations and theses for 14 Ph.D. and four M.S. students. His research has been supported through numerous grants from federal and state agencies.

Dr. Bose’s laboratory has discovered a new class of anti-cancer agents, neuroprotective compounds, and electro-catalysts that hold significant promise to alleviate human sufferings and reduce the cost of Fuel Cells, a clean energy storage device. The new class of anti-tumor agents (phosphaplatins) has the potential to treat a variety of cancers. In preclinical studies, these compounds exhibited superior efficacy with reduced toxicity compared to standard care in ovarian, non-small cell lung, and head and neck cancers, and have shown promise to treat metastasized cancers. The lead compound exhibited effectiveness against 95% of NCI 60- cancer cell lines. Phosplatin Therapeutics, a New York based company is currently preparing an Investigational New Drug application for initiating clinical trial. The second major invention deals with the discovery of neuroprotective compounds that show promise to reduce neuro-toxicity, invariably encountered during cancer treatment, and to treat diabetic retinopathy. Preclinical investigations are currently underway to explore the utility of these compounds to treat a variety of neurological disorders. The third invention entails the discovery of a new platinum-phosphate nano-electrocatalyst that exhibits excellent oxygen reduction properties with ultra-low platinum loading. This catalyst shows exceptional potential to reduce the cost of Fuel Cells to make this clean energy technology affordable by society.